Home  >  News
Medical Device
+ Font Resize -

US FDA approves Respicardia's remede System to treat moderate to severe CSA


Thursday, October 12, 2017, 12:00 Hrs  [IST]

Respicardia, a private medical technology company, announced that it received US Food and Drug Administration (FDA) approval of its remede System, a transvenous implantable neurostimulation system that stimulates the phrenic nerve, and engages the diaphragm to restore natural breathing during sleep in patients with central sleep apnea (CSA). The regulatory approval was based on findings from the remede System pivotal trial, which demonstrated that transvenous neurostimulation with the remede System can significantly reduce the severity of CSA, improve sleep, quality of life and patient satisfaction. The data from the pivotal trial were published in The Lancet in September 2016.

The remede System is indicated for the treatment of moderate to severe CSA in adult patients. CSA is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health. CSA results from the brain's inability to send appropriate signals to the respiratory muscles to stimulate breathing.

"We are thrilled the remede System received FDA approval and are excited to provide this safe and effective therapy that is proven to improve the quality of life for CSA patients," said Bonnie Labosky, president and chief executive officer of Respicardia. "This is a significant step forward in our efforts to offer clinicians a breakthrough and effective treatment option for their patients with CSA."

Current treatment options are limited and there is a large unmet need. The remede System's novel approach to treating CSA is a physiologic treatment that creates negative pressure to move air into the lungs, similar to normal breathing. The system initiates therapy automatically and continues throughout the night without the need for a patient to apply any external equipment.

"The patients at our center treated with the remede System experienced outstanding results and significant reduction in their CSA symptoms," said Maria Rosa Costanzo, MD, principal Investigator of the remede System Pivotal Trial. "Having a therapeutic option for patients with CSA that automatically provides therapy and works throughout the night is a breakthrough treatment for this serious breathing disorder."

In the remede System pivotal trial, 96% of patients were highly satisfied with their therapy. The company plans on an initial limited release that will progress to broader market commercialization.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
IPJPI_150x60en_2017
acssymposium
CPhI-WWW-150x60-stat-v1
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |